

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 13, 2013

NAVIDEA BIOPHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation)	<u>001-35076</u> (Commission File Number)	<u>31-1080091</u> (IRS Employer Identification No.)
--	---	---

<u>425 Metro Place North, Suite 450, Dublin, Ohio</u> (Address of principal executive offices)	<u>43017</u> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective November 13, 2013, the Company appointed Michael M. Goldberg, M.D., to serve on its Board of Directors. Dr. Goldberg was appointed to a term ending at the Company's Annual Stockholders' Meeting in 2014, when he is expected to stand for election for another term ending in 2017. Dr. Goldberg has been a Managing Partner of Montaur Capital Partners since January 2007. Dr. Goldberg served as the Chief Executive Officer of Emisphere Technologies, Inc., from August 1990 to January 2007, Chairman of the Board of Directors from November 1991 to January 16, 2007, and President from August 1990 to October 1995. Prior to that, he served as Vice President of The First Boston Corp., where he was a founding member of the Healthcare Banking Group. He is or has been a Director of Alliqua, Inc., CorNova, Inc., Urigen Pharmaceuticals, Inc. and Adventrx Pharmaceuticals Inc. Dr. Goldberg received a B.S. from Rensselaer Polytechnic Institute, an MD from Albany Medical College of Union University in 1982, and an MBA from Columbia University Graduate School of Business in 1985.

Dr. Goldberg accepted such appointment to serve on the Company's Board of Directors in accordance with the provisions of a Director Agreement, dated November 13, 2013, between the Company and Dr. Goldberg. Pursuant to the terms of the Director Agreement, Dr. Goldberg has acknowledged and agreed that, for as long as he is a member of the Board of Directors, he will not, directly or indirectly, have any power to direct or cause the direction of the voting or disposition of any securities of the Company directly or beneficially owned by Platinum-Montaur Life Sciences LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Management (NY) LLC or Mark Nordlicht, and any other persons or entities controlling, controlled by, or under common control with them (collectively, "Montaur"). Further, the Director Agreement provides that Dr. Goldberg will adhere to the policies and/or procedures adopted by Montaur with respect to the isolation of Dr. Goldberg and material non-public information of the Company obtained by Dr. Goldberg from persons involved in trading or investment activities of Montaur, including, without limitation, policies adopted to comply with the requirements of Section 204A of the Investment Advisers Act of 1940, and regulations promulgated thereunder.

Pursuant to the terms of the Director Agreement, the Company has agreed to, among other things, nominate Dr. Goldberg for election at the Company's Annual Stockholders' Meeting in 2014, and to recommend, support and solicit proxies for his election in the same manner as for the Company's other director nominees standing for election to the Board of Directors at the meeting. The foregoing description of the terms of the Director Agreement is qualified in its entirety by reference to the complete text of the Director Agreement, a copy of which is attached hereto as Exhibit 10.1 and which is incorporated herein in its entirety by reference.

Dr. Goldberg will receive an annual retainer of \$25,000, and earn \$2,500 per board meeting attended in person or \$500 per telephonic board meeting. In connection with Dr. Goldberg's appointment to the Company's Board of Directors, the Company will grant Dr. Goldberg 12,250 restricted shares of the Company's common stock. The restricted stock will be granted under the Company's Fourth Amended and Restated 2002 Stock Incentive Plan, and will vest on the first anniversary of the date of grant. The cash compensation and restricted stock award are the same as paid to other non-executive directors of the Company for their service in 2013. On November 15, 2013, the Company issued a press release entitled "Navidea Biopharmaceuticals Adds New Member to Board of Directors" in connection with the appointment of Dr. Goldberg to the Board of Directors. A copy the Company's November 15, 2013, press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-K and other filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

---

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

*Exhibit  
Number*

*Exhibit Description*

10.1	Director Agreement, dated November 13, 2013, by and between Navidea Biopharmaceuticals, Inc. and Michael M. Goldberg, M.D.
99.1	Navidea Biopharmaceuticals, Inc. press release dated November 15, 2013, entitled "Navidea Biopharmaceuticals Adds New Member to Board of Directors."

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Navidea Biopharmaceuticals, Inc.

Date: November 19, 2013

By: /s/ Brent L. Larson  
Brent L. Larson, Executive Vice President and  
Chief Financial Officer

---

**DIRECTOR AGREEMENT**

This DIRECTOR AGREEMENT is made as of November 13, 2013 (the "Agreement"), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Michael M. Goldberg, M.D., an individual with an address of c/o Montaur Capital Partners, 152 West 57th Street, 4th floor c/o Platinum, New York, New York 10019 (the "Director").

WHEREAS, the Company wishes to appoint the Director to its Board of Directors, and desires to enter into an agreement with the Director with respect to such appointment; and

WHEREAS, the Director is willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with the provisions of this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:

1           Position. Subject to the terms and provisions of this Agreement, the Company shall cause the Director to be appointed a Director of the Company in the class of directors up for election at the 2014 Annual Meeting of Stockholders (the "2014 Annual Meeting") immediately upon the execution of this Agreement, and the Director hereby agrees to serve the Company in such position, upon the terms and conditions hereinafter set forth, and in accordance with the duties imposed by Delaware law, the Company's Amended and Restated Certificate of Incorporation, the Company's Amended and Restated By-Laws (the "Bylaws") and applicable stock exchange regulations provided, however, that the Director's continued service on the Board of Directors of the Company (the "Board") after the 2014 Annual Meeting shall be subject to approval by the Company's stockholders, provided, further, that the Company agrees to nominate the Director for election at the 2014 Annual Meeting and recommend, support and solicit proxies for the election of the Director at the 2014 Annual Meeting in the same manner as for the Company's other Director nominees standing for election to the Board of Directors at the 2014 Annual Meeting.

2           Duties.

(a)           During the Directorship Term (as defined herein), the Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate committees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

(b)           The Director will use his reasonable best efforts to promote the interests of the Company and devote such time to the Company's affairs as required to appropriately discharge his duties and legal obligations as a Director. Other than as set forth above, the Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company. At such time as the Board receives such notification, the Board may require the resignation of the Director if it determines that such business activity does in fact materially interfere with the performance of the Director's duties, services and responsibilities hereunder.

3           Compensation.

(a)           The Company agrees to pay Director a fee of \$25,000 as an annual retainer, plus \$2,500 for each meeting of the Board of Directors attended in person, and \$500 for each meeting in which the Director participates by telephone. Additionally, Director will receive a restricted stock award under the Company's Fourth Amended and Restated 2002 Stock Incentive Plan of 12,250 shares of common stock, vesting on the first anniversary of the date of grant. The Company and the Director acknowledge that under the Bylaws of the Company, the Board of Directors shall have authority to fix the compensation of directors.

(b)           During the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared to out-of-pocket expenses of the Director) must be approved in advance by the Company.

---

(c) The Company will maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

(d) The Director's status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

4 Directorship Term. The "Directorship Term," as used in this Agreement, shall mean the period commencing on the date hereof and terminating on the earlier of the date of the next annual stockholders meeting and the earliest of the following to occur:

- (a) the death of the Director;
- (b) the termination of the Director from his membership on the Board by the mutual written agreement of the Company and the Director;
- (c) the removal of the Director from the Board in accordance with the Bylaws and Delaware law; and
- (d) the resignation by the Director from the Board.

5 Director's Representations and Acknowledgment.

(a) The Director acknowledges and agrees that his position as member of the Board will result in him being deemed to be an "affiliate" of the Company for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder (collectively, the "Securities Laws").

(b) The Director acknowledges and agrees that for as long as he is a member of the Board of Directors he will not, directly or indirectly, have any power to direct or cause the direction of voting or disposition of any securities of the Company directly or beneficially owned by Platinum-Montaur Life Sciences LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Management (NY) LLC or Mark Nordlicht, and any other persons or entities controlling, controlled by, or under common control with them (collectively, "Montaur"). Further, the Director agrees that he will adhere to the policies and/or procedures adopted by Montaur with respect to the isolation of the Director and material non-public information of the Company obtained by Director from persons involved in trading or investment activities of Montaur, including without limitation policies adopted to comply with the requirements of Section 204A of the Investment Advisers Act of 1940, and regulations promulgated thereunder.

(c) The Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any officer, director, employee, stockholder, representative or agent of the Company or any of their respective affiliates with regard to this Agreement.

## 6 Company's Representations and Acknowledgment.

(a) The Company acknowledges and agrees that, subject to compliance by Director and Montaur with the provisions of Section 5(b), as long as the Director is a member of the Board of Directors none of Platinum-Montaur Life Sciences LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Management (NY) LLC or Mark Nordlicht, and any other persons or entities controlling, controlled by, or under common control with them, shall be characterized in any filing made by the Company with the United States Securities and Exchange Commission as an "affiliate" of the Company for purposes of the Securities Laws solely by virtue of the Director's position as a member of the Board of Directors.

(b) The Company acknowledges and agrees that all of the benefits and terms granted by Company herein are at least as favorable as the benefits and terms granted by the Company in any written agreement with any current Director.

## 7 Director Covenants.

( a ) *Unauthorized Disclosure.* The Director agrees and understands that in the Director's position with the Company, the Director has been and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company's products, services, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential, and proprietary and in the nature of trade secrets. The Director agrees that during the Directorship Term and thereafter, subject to his fiduciary duties, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information (A) is or becomes publicly known or generally known in the Company's industry other than as a result of the Director's breach of his obligations hereunder, (B) is lawfully obtained from a source other than the Company that was not under, and did not impose, an obligation of confidentiality with respect to such information; (C) is independently developed by Director or his Affiliates without violating any of his obligations under this Agreement; and (D) is or becomes known by the Director other than through disclosure by the Company in the course of the Directorship Term; and (ii) the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no geographical or territorial restriction. Upon termination of the Directorship Term, the Director will promptly destroy all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director's position with the Company during or prior to the Directorship Term, provided that the Company shall retain such materials and make them available to the Director if requested by him in connection with any litigation against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

(b) *Company Policies.* Director acknowledges that he has received and reviewed a copy of the Company's Code of Conduct, and its Ethics and Securities Trading Policy for Officers, Directors and Key Employees (the "Policies"), and understands and agrees that he will strictly comply with all the requirements of the Policies during the Directorship Term and so for so long thereafter as specifically required by the Policies.

(c) *Non-Solicitation.* During the Directorship Term and for a period of two (2) years thereafter, the Director shall not interfere with the Company's relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee or customer (including those reasonably expected to be a customer) of the Company or otherwise had a material business relationship with the Company.

(d) *Remedies.* The Director agrees that any breach of the terms of this Section 7 could result in irreparable injury and damage to the Company for which the Company could have no adequate remedy at law. The Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to seek an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all of his affiliates, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not

limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not have entered into this Agreement had the Director not agreed to the provisions of this Section 7.



(e) Survival. The provisions of this Section 7 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 7.

8 Company Covenants. The Company agrees that as long as the Director is a member of the Board of Directors, should the Company enter into any subsequent agreement with any current or future Director affiliated with a hedge fund or private equity fund owning securities of the Company that provides for benefits or terms more favorable than those contained in this Agreement, then this Agreement shall be deemed to be modified to provide the Director with those more favorable benefits and terms.

9 Non-Waiver of Rights. The failure to enforce at any time the provisions of this Agreement or to require at any time performance by the other party hereto of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement or any part hereof, or the right of either party hereto to enforce each and every provision in accordance with its terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent time.

10 Notices. Every notice relating to this Agreement shall be in writing and shall be given by personal delivery, overnight delivery or by registered or certified mail, postage prepaid, return receipt requested; to:

If to the Company:

Navidea Biopharmaceuticals, Inc.  
425 Metro Place North  
Suite 450  
Dublin, OH 43017-1367  
Attn: Brent L. Larson, Executive Vice President and Chief Financial Officer  
Telephone: (614) 793-7500  
Facsimile: (614) 793-7522

with a copy (which shall not constitute notice) to:

Porter, Wright, Morris & Arthur LLP  
41. South High Street, Suites 2800-3200  
Columbus, Ohio 43215  
Attn: William J. Kelly, Esq.  
Telephone: (614) 227-2136  
Facsimile: (614) 395-4401

If to the Director:

Michael M. Goldberg, M.D.  
c/o Montaur Capital Partners  
152 West 57th Street  
4th floor c/o Platinum  
New York, New York 10019  
Telephone: (914) 572 8953  
Email: mgoldberg@montaurcap.com

with a copy (which shall not constitute notice) to:

Platinum Management (NY) LLC  
152 West 57th Street  
4th Floor  
New York, New York 10019  
Attn: David Ottensoser, General Counsel  
Telephone: (212) 582-2222  
Facsimile: (212) 582 2424

and

Kleinberg, Kaplan, Wolff & Cohen, P.C.  
551 Fifth Avenue, 18th Floor  
New York, New York 10176  
Attn: Christopher P. Davis  
212-986-6000 Phone  
212-986-8866 Fax

Either of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant to this Section 10.

11 Binding Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns, as applicable. Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion of this Agreement without the prior written consent of the other party.

1 2 Entire Agreement. This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject matter.

1 3 Severability. If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.

1 4 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard and determined in the Court of Chancery of the State of Delaware and the parties hereto hereby consent to the jurisdiction of such courts in any such action or proceeding; provided, however, that neither party hereto shall commence any such action or proceeding unless prior thereto the parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject of such action or proceeding through mediation by an independent third party.

15 Modifications. Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument in writing duly signed by the party to be charged.

1 6 Tense and Headings. Whenever any words used herein are in the singular form, they shall be construed as though they were also used in the plural form in all cases where they would so apply. The headings contained herein are solely for the purposes of reference, are not part of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.

1 7 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board of Directors, and the Director has hereunto set his hand, on the day and year first above written.

[signatures on following page]

**NAVIDEA BIOPHARMACEUTICALS, INC.**

By: /s/ Mark J. Pykett  
Mark J. Pykett, V.M.D., Ph.D.,  
Chief Executive Officer

---

**DIRECTOR**

/s/ Michael M. Goldberg, M.D.  
Michael M. Goldberg, M.D.

---



Press Release

**FOR IMMEDIATE  
RELEASE**

## **Navidea Biopharmaceuticals Adds New Member to Board of Directors**

DUBLIN, OHIO – November 15, 2013 – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.

Michael M. Goldberg has been a Managing Partner of Montaur Capital Partners since January 2007. Dr. Goldberg served as the Chief Executive Officer of Emisphere Technologies, Inc., from August 1990 to January 2007, Chairman of the Board of Directors from November 1991 to January 16, 2007 and President from August 1990 to October 1995. Prior to that, he served as Vice President of The First Boston Corp., where he was a founding member of the Healthcare Banking Group. He is or has been a Director of Alliqua, Inc., CorNova, Inc., Urigen Pharmaceuticals, Inc. and Adventrx Pharmaceuticals Inc. Dr. Goldberg received a B.S. from Rensselaer Polytechnic Institute, an MD from Albany Medical College of Union University in 1982 and an MBA from Columbia University Graduate School of Business in 1985.

"We are pleased to have Michael join the Board," said Gordon Troup, Chairman of the Navidea Board of Directors. "Michael brings a wealth of knowledge of the financial and biopharmaceutical industries that make him an extremely valuable resource to our Board as we continue to execute on our growth plans."

"I am excited to be joining the Board and have the opportunity to help deliver the greatest possible impact to patients and the medical community and return for investors with Navidea's industry leading precision diagnostic products and technologies," said Dr. Goldberg. "I look forward to working with the Board and Management to help Navidea realize the potential I believe Lymphoseek®, the Company's pipeline, and Navidea's business model have."

### **About Navidea Biopharmaceuticals, Inc.**

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and RIGScan™, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit [www.navidea.com](http://www.navidea.com).

---

– more –

**NAVIDEA BIOPHARMACEUTICALS**  
**ADD – 2**

*The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.*

**Source:** Navidea Biopharmaceuticals, Inc.

**Contact:** Navidea Biopharmaceuticals  
Brent Larson, 614-822-2330  
Executive VP & CFO

Sharon Correia, 978-655-2686  
Associate Director, Corporate Communications

###

- end -

---